Treatment of Kawasaki disease using locally product intravenous immunoglobulin.

Sangtawesin, Chaisit; Kirawitaya, Thawatchai; Layangkool, Thanarat; Nawasiri, Wipajaree; Vimolsarawong, Nawaporn.
Artículo en Inglés | IMSEAR | ID: sea-43062

Documentos relacionados

  1. Incomplete Kawasaki disease with muscular weakness and bladder retention: a case report.
  2. Retrospective analysis of children diagnosed with Kawasaki disease.
  3. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
  4. Kawasaki Disease with Hepatobiliary Manifestations.
  5. Clinical Manifestations and Laboratory Findings of Kawasaki Disease: Beyond the Classic Diagnostic Features.
  6. Development of a nomogram prediction model for early identification of persistent coronary artery aneurysms in kawasaki disease.
  7. Stratified therapy for Kawasaki disease using a new scoring system to predict the response to a lower dose of intravenous immunoglobulin therapy.
  8. A registry study of Kawasaki disease patients with coronary artery aneurysms (KIDCAR): a report on a multicenter prospective registry study three years after commencement.
  9. Effectiveness of two same-manufacturer intravenous immunoglobulin for Kawasaki disease.
  10. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study.